Hosted on MSN6mon
Annovis Bio Gains FDA Approval for New Form of Neurodegenerative Drug
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has received approval from the U.S. Food and Drug Administration (FDA) to transition to a new solid form of buntanetap in future clinical trials.
Hosted on MSN20d
FDA Accepts Revised Protocol for Annovis Bio’s Phase 3 Alzheimer’s Study
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced that the U.S. Food and Drug Administration (FDA) has accepted an updated protocol for the company’s pivotal Phase 3 Alzheimer’s (AD ...